Press release

Double-digit growth in profits for the 18th consecutive year – dividend increase to CHF 14 per registered share proposed

Tuesday, 11 March 2014, ↓ directly to download

Galenica increased consolidated net sales by 2.0% to CHF 3,359.4 million in 2013. On a comparable basis, profit before deduction of minority interests increased by 7.8% to CHF 296.2 million and after deduction of minority interests by 1.6% to CHF 257.6 million. Taking into account positive one-time effects due to IAS 19 and the settlement of an international tax case, net profit saw a double-digit growth for the 18th consecutive year, by 21.1% to CHF 334.8 million before and by 16.1% to CHF 296.2 million after deduction of minority interests. At the Annual General Meeting 2014, the Board of Directors will recommend a dividend increase of 27.3% to CHF 14.00 per registered share.

_Among the highlights of 2013 were US Food and Drug Administration (FDA) approvals for Injectafer® for the treatment of iron deficiency anaemia and for Velphoro® to control serum phosphorus levels in patients with chronic kidney disease on dialysis. Further milestones were the acquisition of Medifilm, the leading Swiss company in the field of blister packaging for medicines, as well as the acquisition of a minority stake in the pharmacy Bahnhof Apotheke Zurich.

_In 2014, Vifor Pharma will continue to expand Ferinject® in international markets, will support its partner Luitpold Pharmaceuticals, Inc. with the launch of Injectafer® in the US and will prepare further registrations and the commercialisation of Velphoro®. Logistics, Retail and HealthCare Information will continue to expand their business activities and to implement the projects already launched in order to optimise processes and improve profitability.

_Galenica management has set itself the target of achieving at least the same level of profit in 2014 as in the previous year on a comparable basis, both before and after deduction of minority interests.

EBIT, EBITDA and consolidated net profit of the Galenica Group

in million CHF

2013

2012

in % 

Pharma

269.3

257.1

+4.8

Logistics

31.1

30.7

+1.3

Retail

63.0

60.3

+4.5

HealthCare Information

4.0

4.3

-5.7

Other and eliminations

23.2

(0.4)

-

Group EBIT

390.6

352.0

+11.0

Group EBITDA

466.2

428.0

+8.9

Net profit
Attributable to:

334.8

276.5

+21.1

_Shareholders of Galenica Ltd.

296.2

255.2

+16.1

_minority interests

38.6

21.3

+81.2

Read more

Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).

contact

Julien Vignot

Julien Vignot

Head Investor Relations


Galenica Ltd.

Investor Relations
Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 81 11
Fax:
+41 58 852 81 12

Christina Hertig

Christina Hertig

Head of Corporate Communications


Galenica Ltd.

Corp. Communications
Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 85 17
Fax:
+41 58 852 85 58

Send link

Send as link



Links

  •